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ABSTRACT
Sporadic colorectal cancer (CRC) insurgence and progression depend on the 
activation of Wnt/β-catenin signaling. Dickkopf (DKK)-1 is an extracellular inhibitor 
of Wnt/β-catenin signaling that also has undefined β-catenin-independent actions. 
Here we report for the first time that a proportion of DKK-1 locates within the nucleus 
of healthy small intestine and colon mucosa, and of CRC cells at specific chromatin 
sites of active transcription. Moreover, we show that DKK-1 regulates several cancer-
related genes including the cancer stem cell marker aldehyde dehydrogenase 1A1 
(ALDH1A1) and Ral-binding protein 1-associated Eps domain-containing 2 (REPS2), 
which are involved in detoxification of chemotherapeutic agents. Nuclear DKK-1 
expression is lost along CRC progression; however, it remains high in a subset (15%) 
of CRC patients (n = 699) and associates with decreased progression-free survival 
(PFS) after chemotherapy administration and overall survival (OS) [adjusted HR, 1.65; 
95% confidence interval (CI), 1.23-2.21; P = 0.002)]. Overexpression of ALDH1A1 
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INTRODUCTION
Colorectal cancer (CRC) is an important contributor 
to cancer mortality and morbidity [1]. Despite advances in 
therapy for CRC patients, approximately 20-45% of those 
who undergo curative resection subsequently develop 
tumor recurrence or distant metastasis [2]. Adjuvant 
chemotherapy has demonstrated survival benefits in 
patients with advanced-stage CRC, but the lack of patient 
selection leads to unnecessary overtreatment and financial 
cost [3]. To facilitate individually tailored treatment for 
CRC, predictive biomarkers are needed to identify patients 
who are at high risk for recurrence and/or poor prognosis. 
Abnormal activation of the Wnt/β-catenin pathway 
due to mutation of APC, CTNNB1/β-catenin or AXIN 
genes is the initial event and a driving force of colorectal 
tumorigenesis [4]. Dickkopf (DKK)-1 is one of the 
four members of a family of secreted extracellular Wnt 
inhibitors that block signaling from plasma membrane 
Wnt-receptor complexes [5, 6]. Paradoxically, however, 
DKK-1 modulates proliferation and survival of cancer 
cells in which the Wnt/β-catenin pathway is constitutively 
activated by mutations in genes encoding intracellular 
pathway components, or independently of β-catenin 
transcriptional activity [7, 8]. Overall, available data 
indicate the existence of uncharacterized actions of DKK-
1 that are independent of the inhibition of Wnt signaling 
at plasma membrane.
In colon cancer cells, DKK-1 inhibits proliferation 
both in vitro and in immunodeficient mice [8] and its 
expression is linked to an E-cadherin-dependent adhesive 
phenotype [9], supporting a tumor suppressor role for this 
protein. Moreover, several studies indicate that DKK-1 
expression is downregulated along colorectal adenoma-
carcinoma transition and at late CRC stages but the clinical 
consequences are unknown [8, 10]. By contrast, a recent 
study indicates that preoperative serum levels of DKK-1 
protein seem to be a predictive marker of tumor invasion 
and relapse in stage II-III colon cancer [11]. DKK-1 is 
also downregulated in chronic lymphocytic leukemia 
and papillary thyroid cancer [12, 13]. These potential 
protective effects contrast with the overexpression of 
DKK-1 in several types of cancer associated with a poor 
prognosis [14-20], and make the role of DKK-1 as tumor 
suppressor or metastasis promoter a matter of debate [21]. 
In this study, we aimed to decipher the role of DKK-
1 in CRC by investigating its expression in cultured human 
colon carcinoma cells and in normal small intestine and 
colon mucosa and colorectal cancer, and by assessing the 
relation of DKK-1 expression with the clinical outcome 
and the benefit to systemic therapy in CRC patients.
RESULTS
DKK-1 protein partially locates within the cell 
nucleus
First, we analyzed the expression of DKK-1 protein 
in human intestine mucosa using immunofluorescence 
multispectral microscopy of healthy individuals. 
Unexpectedly, we found nuclear staining in a high 
proportion (62.8%) of differentiated cells (i.e. enterocytes 
and mucosecretory goblet cells) located at the epithelium 
of colon (Fig. 1A) and small intestine (Fig. 1B) crypts. 
In the latter, nuclear DKK-1 expression was also detected 
in enteroendocrine cells at the bottom of the crypts, as 
revealed by co-expression of chromogranin A (Fig. 1B). 
Cytoplasmic staining was diffusely present in small 
intestine enterocytes and enteroendocrine cells (Fig. 1B). 
By contrast, stem cells at the bottom of the crypts and 
proliferating undifferentiated cells in the basal epithelia 
contained cytoplasmic DKK-1 but lacked nuclear DKK-1 
in both colon and small intestine (Figs. 1A and B).
Next, we studied the expression of DKK-1 in human 
colon carcinoma cells both in vitro and in a large cohort 
of metastatic CRC patients. DKK-1 was found partially 
located within the nucleus of SW480-ADH CRC cells, as 
shown by punctate immunofluorescence staining (Fig. 2A) 
and confirmed and quantified by Western blot analysis of 
cellular fractions (Fig. 2B). Nuclear DKK-1 accounted 
for 7% of total protein. We also detected nuclear DKK-
1 via proteomic analysis (Supplementary Fig. S1) and 
by transfecting DLD-1 CRC cells lacking endogenous 
expression with a DKK-1 gene (DLD-1/DKK-1 cells) 
(Supplementary Fig. S2). 
To identify the precise intranuclear location of 
DKK-1, we performed double immunofluorescence 
assays. DKK-1 did not colocalize with either fibrillarin 
or 2,2,7-trimethylguanosine cap (TMG-cap), indicating 
that it is absent from the nucleolus and nuclear speckles, 
respectively (Fig. 2C). Sporadic colocation of DKK-
1 with acetylated histone H4 indicated its presence in 
transcriptionally active chromatin (Fig. 2C), which 
was confirmed by in vivo transcription assays based on 
the incorporation of 5’-fluorouridine (FU) into nascent 
RNA, followed by immunofluorescence using an anti-
and REPS2 associates with nuclear DKK-1 expression in tumors and correlates with 
decreased OS (P = 0.001 and 0.014) and PFS. In summary, our findings demonstrate 
a novel location of DKK-1 within the cell nucleus and support a role of nuclear DKK-1 
as a predictive biomarker of chemoresistance in colorectal cancer.
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Figure 1:  DKK-1 is present within the nucleus of differentiated human intestinal cells. A, left, expression of DKK-1 in 
human colon crypts by immunofluorescence showing nuclear location in enterocytes and goblet cells at the tip of crypts, which is absent 
in proliferative and stem cells at the bottom. Statistical differences in nuclear DKK-1 expression were observed between upper and lower 
sections of the crypts (P = 10-20); right, data correspond to quantification of 320 randomly distributed crypts from 16 healthy individuals. 
B, strong nuclear and cytoplasmic DKK-1 expression in small intestine epithelial cells at the villus tips and in chromogranin-expressing 
enteroendocrine cells at the crypt bottoms. In both panels, scale bars: left images, 100 µm; right images, 20 µm. Nuclei were stained with 
DAPI.
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BrdU antibody (Fig. 2C, lowest panels). Moreover, 
immunoelectron microscopy analyses using double 
immunogold labeling for 5’-FU incorporation sites and 
DKK-1 revealed the presence of DKK-1 in euchromatin 
but not in transcription-free nuclear domains such 
as heterochromatin or nuclear speckles visualized as 
interchromatin granule clusters (IGC) (Fig. 2D, above). 
Moreover, specific sites of colocation of nascent RNA and 
DKK-1 were found (Fig. 2D, below). 
We examined whether ectopic DKK-1 could affect 
Wnt/β-catenin or non-canonical Wnt signaling in DLD-
1 cells. DKK-1 did not affect the transcriptional activity 
of β-catenin (Supplementary Fig. S3A) or the expression 
of two Wnt/β-catenin targets, c-Myc and cyclin D1 
(Supplementary Fig. S3B). Likewise, DKK-1 did not 
change the levels of total or phosphorylated JNK or of 
GSK-3β activity in the cytosol (Supplementary Fig. S3C 
and D). Taken together, these results indicate that the 
tumor suppressive action of DKK-1 in DLD-1 cells [8] 
in which the Wnt/β-catenin pathway is endogenously 
activated due to APC mutation is independent of Wnt.
Nuclear DKK-1 in tumor cells associates with 
worse progression-free and overall survival in 
CRC patients
Next, we examined the expression of DKK-1 
protein in adenomas and a cohort of 699 CRC patients 
Figure 2: DKK-1 partially locates in the cell nucleus at sites of active transcription. A, immunofluorescence and confocal 
microscopy images showing DKK-1 expression in the cytoplasm and nucleus of SW480-ADH colon cancer cells. Scale bar, 10 µm. B, 
upper, expression of DKK-1 protein in total (T), cytoplasmic (CYT) and nuclear (NUC; 10-fold concentrated) fractions of SW480-ADH 
cells by Western blot analysis. Lamin B and β-tubulin were used as nuclear and cytoplasmic markers, respectively. Lower, Western blot 
analysis of DKK-1 protein in nuclear extracts of SW480-ADH and DLD-1/DKK-1 cells using a DKK-1 antibody pre-incubated (overnight, 
4ºC) with a specific blocking peptide. C, lack of immunofluorescence co-staining with fibrillarin and TMG-cap shows that DKK-1 locates 
outside but close to nucleoli and nuclear speckles in SW480-ADH cells. By contrast, partial colocation with acetylated Histone H4 and 
5’-FU (arrowheads) indicates that DKK-1 resides at active transcription sites. Scale bars: three left columns, 5 µm; right column, 0.8 µm. 
D, immunoelectron microscopy analysis using primary mouse anti-BrdU to detect 5’-FU incorporation into nascent RNA and rabbit anti-
DKK-1 antibodies, and secondary goat anti-rabbit or anti-mouse IgG coupled to 15 nm or 10 nm gold particles, respectively. Upper, 5’-FU 
incorporation sites and DKK-1 appear distributed in euchromatin regions while they are absent in interchromatin granule clusters (IGC, 
dotted area), which are transcription-free nuclear domains. Lower, nascent RNA and DKK-1 protein colocate in euchromatin (arrows). 
Scale bars: 100 nm.
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with clinical follow-up (Supplementary Table S1). As in 
healthy individuals, DKK-1 protein was detected both in 
the nucleus and in the cytoplasm of normal enterocytes 
in adjacent non-tumoral colorectal mucosa; in contrast, 
three patterns of expression were found in tumors: absence 
of DKK-1, presence of only cytoplasmic DKK-1, and 
presence of DKK-1 in both cytoplasm and nucleus (Fig. 
3A). Staining of complete sections of colorectal tumors 
showed that the pattern of DKK-1 protein expression 
was mostly homogeneous; no differences were found 
between tumor areas. The nuclear localization of DKK-
1 protein was confirmed by using different antibodies 
(Supplementary Fig. S4). Data quantification across the 
series revealed absence of nuclear DKK-1 in 22% of 
adenomas and 75% of carcinomas, and a loss of DKK-1 
expression during tumor progression that occurred earlier 
in the nucleus than in the cytoplasm (Fig. 3B). Remarkably, 
nuclear DKK-1 levels remained high in a subset (n = 103, 
14.7%) of CRC. This prompted us to analyze whether 
the presence of nuclear DKK-1 within the primary tumor 
could affect clinical behavior. Nuclear DKK-1 expression 
was associated with decreased Progression-Free Survival 
(PFS) after chemotherapy administration (P = 0.001) and 
Overall Survival (OS) (P = 0.002) (Fig. 3C). The hazard 
ratio for death in patients with nuclear DKK-1 expressing 
tumors was 1.65 (IC 95%; 1.23-2.21). This remained true 
for patients who received 5’-FU (n = 399, P = 0.011), 
FOLFIRI (n = 95, P = 0.012) or FOLFOX (n = 205, P = 
0.031) for both OS (Fig. 3D) and PFS (Supplementary Fig. 
S5). These findings suggested a role of nuclear DKK-1 in 
chemosensitivity and survival in CRC patients.
DKK-1 regulates the expression of the cancer-
related genes ALDH1A1 and REPS2
The location of nuclear DKK-1 in a subset of sites 
of active transcription indicates that it participates in the 
regulation of specific target genes. To identify DKK-1 
targets we used DLD-1/DKK-1 and DLD-1/Mock cells to 
perform: a) a comparative global transcriptomic analysis; 
and b) chromatin immunoprecipitation assays followed 
Figure 3: Nuclear DKK-1 expression decreases during CRC progression and associates with shorter patient PFS and 
OS. A, immunofluorescence for DKK-1 and DNA (DAPI) in healthy colon tissue and in adenocarcinomas that express only cytosolic 
(CYT), cytosolic and nuclear (CYT+NUC) or no (negative) DKK-1 protein. Scale bars: 25 µm. B, quantification of DKK-1 expression in 
cytoplasm and nucleus of healthy colon tissue, adenomas and adenocarcinomas. The number of samples is indicated. C, and D, association 
of nuclear DKK-1 with worse PFS and OS (Kaplan-Meier curves) of CRC patients who received any systemic (C) or specific chemotherapy 
regimens (OS) (FOLFOX, FOLFIRI, 5’-FU) (D). Red curves: patients with nuclear DKK-1 expression; blue curves: absence of nuclear 
DKK-1 expression. Patients at risk for the specific event are detailed for each time point.
Oncotarget5908www.impactjournals.com/oncotarget
Figure 4: Effects of DKK-1 induction on gene expression in DLD-1 cells. A, left, plot profile of the expression values along 
arrays for the probes selected as differentially expressed (Padjust 0.05) after DKK-1 induction. Signal intensities are scaled to the same 
range and the normalized log intensity values of the probes were centered to the median value of each probe set. A loess (locally weighted 
polynomial regression) fit line describes the overall profile of the up-regulated (red) and down-regulated (blue) genes. Right, log2 Fold-
Change (FC) representation of the differentially expressed genes. The color intensity is proportional to the value (DKK-1 is not included). 
B, validation of DKK-1 target genes in DLD-1/DKK-1 cells. RNA levels were measured by qRT-PCR 24 h after DKK-1 induction by 
doxycyclin. Fold-change with respect to levels in DLD-1/Mock cells is represented. C, ChIP-seq analysis of DKK-1 in DLD-1 cells. 
Examples of the genome-wide mapping of DKK-1 binding sites. Significant DKK-1 peaks detected by Model-based Analysis of ChIP-Seq 
are represented in the samples analyzed. The corresponding Refseq gene is shown in blue. The vertical red line in the chromosome indicates 
the location of the peak. 
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by ultradeep sequencing (ChIP-seq). We obtained 27 
differentially expressed probes (Fig. 4A; the complete 
list of genes is deposited in the GEO database accession 
no. GSE35272). Among candidate target genes identified 
in the transcriptomic studies, aldehyde dehydrogenase 
1A1 (ALDH1A1), aldo-keto reductase family 1 member 
C3 (AKR1C3) and Ral-binding protein 1-associated Eps 
domain-containing 2 (REPS2) were particularly interesting 
as they have been implicated in the detoxification of 
xenobiotics and chemotherapeutic agents [22-25] (Fig. 
4B). Moreover, ALDH1A1 has been proposed as a marker 
of normal and malignant stem cells in colon and other 
tissues, although there is no consensus on its association 
with prognosis or patient survival [26-28]. In the ChIP-
seq, 200 binding sites (average peak width 150) with 
significant tag enrichment were identified throughout the 
genome (Fig. 4C). Up to 80 individual DKK-1-binding 
sites (40%) were associated with genes (GEO accession 
no. GSE31170), three of which were coincident with 
those found in the transcriptomic study (REPS2, IQGAP2, 
LOC554202).
Consistent with their regulation by DKK-1, the RNA 
and protein expression of ALDH1A1, AKR1C3 and REPS2 
was higher in CRC tumors containing nuclear DKK-1 than 
in those that lacked it (Fig. 5A) and it was associated with 
the presence of nuclear DKK-1 (Fig. 5B and C). Only two 
(0.3%) cases expressed nuclear DKK-1 and none of the 
three target genes. Moreover, co-expression of nuclear 
DKK-1 and cytoplasmic ALDH1A1 was demonstrated in 
the same tumor cells (Fig. 5D).
Concomitant expression of ALDH1A1, 
REPS2, and nuclear DKK-1 associates with 
chemoresistance in colorectal cancer
The relation of the three DKK-1 target genes 
with the benefit to chemotherapy was investigated in 
CRC patients. ALDH1A1 and REPS2 expression, but 
not that of AKR1C3 (not shown), was associated with 
decreased OS (P = 0.001 and 0.014, respectively) and 
PFS (P = 0.005 and 0.009, respectively) (Fig. 6A and 
Table 1). Importantly, tumors with nuclear DKK-1 and 
Figure 5: DKK-1 induces ALDH1A1, REPS2 and AKR1C3 genes involved in chemotherapy detoxification. A, expression 
of ALDH1A1, REPS2 and AKR1C3genes at the RNA (left, qRT-PCR) and protein (right, immunohistochemistry) level in primary (n = 12) 
and metastatic (n = 13) colon tumors expressing or not nuclear DKK-1 as compared to healthy (n = 10) colon mucosa (*, P < 0.05). B, 
association of nuclear DKK-1 with ALDH1A1, REPS2 and AKR1C3 expression in the series of 699 CRC patients. C, immunohistochemical 
analysis of ALDH1A1, REPS2 and AKR1C3 expression in representative nuclear DKK-1-positive (strong staining) and -negative (weak 
staining) tumors. Scale bars: 50 µm. D, immunohistochemical analysis of DKK-1 and ALDH1A1 protein co-expression in tumors. Scale 
bars: 25 µm.
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co-expression of at least one of the three target genes (n 
= 101, 14.4%) showed a significant reduction in patient 
OS as compared to cases with absence of nuclear DKK-1 
and expression of any of the three genes (n = 55, 7.9%) 
(P = 0.010). Notably, no effect of DKK-1 on sensitivity 
to oxaliplatin, irinotecan or 5’-FU was found in vitro 
(DLD-1 and RKO cells), possibly because ectopic DKK-1 
expression rendered a level of nuclear DKK-1 protein that 
was similar to that of the endogenous protein in SW480-
ADH cells (7%, Fig. 2) but substantially lower than that 
found in tumors (Fig. 6B and Supplementary Fig. S6). In 
line with this, the expression level of ALDH1A1, REPS2, 
and AKR1C3 was lower in DLD-1/DKK-1 cells than in 
tumors with nuclear DKK-1 (Supplementary Fig. S7). This 
result suggests that extracellular signals, either paracrine 
soluble factors or matrix components, may contribute in 
vivo, but not in vitro where they are absent, to control the 
amount of nuclear DKK-1.
Figure 6: Expression of ALDH1A1 and REPS2 associates with decreased patient survival. A, effect of ALDH1A1 and 
REPS2 genes on patient PFS and OS. Kaplan-Meier curves of patients whose primary tumors expressed (red) or not (blue) ALDH1A1 
or REPS2 genes. B, nuclear-to-cytoplasmic ratio of DKK-1 expression in a subset of CRC (n = 50) and healthy colonic mucosa (n = 10) 
as compared with DLD-1 and RKO colon carcinoma cells lacking endogenous DKK-1 expression that were infected with lentiviruses 
encoding DKK-1 (DKK-1) or no ectopic gene (Mock). Mean values for each group are indicated by dashed lines (black, CRC with nuclear 
DKK-1 expression; orange, healthy mucosa; purple, cell lines with DKK-1 expression) and median values by solid lines.
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DISCUSSION
Our results show for the first time that a proportion 
of DKK-1 is located in the nucleus of human enterocytes 
and malignant epithelial cells in CRC and regulates the 
expression of a number of genes including several that are 
relevant for cancer. The location of nuclear DKK-1 in a 
subset of sites of active transcription indicates that it is not 
an essential component of the chromatin or of the basal 
transcriptional machinery but, rather, that it participates in 
the transcription of specific target genes. 
In recent years, the concept has emerged that proteins 
that exert a function in a given subcellular compartment 
may play additional roles in different locations [29]. Thus, 
cytoskeletal and even plasma membrane proteins have 
been found within the cell nucleus, in some cases being 
involved in gene transcription [30, 31]. The mechanism 
of DKK-1 translocation into the cell nucleus is unknown. 
Although the mature DKK-1 protein (37 kDa) does not 
have a conventional nuclear localization signal, it has 
been proposed that small molecules including proteins of 
molecular mass up to 40 kDa may enter the nucleus by 
passive diffusion [32] or be imported by interaction with 
other proteins that contain a functional nuclear localization 
signal [33].
The presence of a fraction of DKK-1 within the 
nucleus controlling gene expression might contribute to 
explain the recently proposed role of DKK-1 to inhibit 
colon cancer-initiating cell growth through mechanisms 
other than the blockade of the Wnt/β-catenin signaling 
pathway [34]. Curiously, the inhibition of cell proliferation 
observed in mouse intestinal crypts by forced expression 
of exogenous Dkk-1 has been interpreted as the 
requirement of Wnt/β-catenin signaling [35]. Likewise, 
increased proliferation of colon epithelial cells upon 
reduced expression of Dkk-1 has been associated with 
increased transcriptional activity of β-catenin [36]. Our 
data, however, provide an alternative explanation for 
the β-catenin-independent growth inhibitory effects of 
DKK-1 in DLD-1 colon carcinoma [8], H28 and MS-1 
mesothelioma [7] and HeLa cervical cancer [37] cells. 
Recently, it has been demonstrated that colorectal 
cancer cells can respond to exogenous and autocrine 
Wnt ligands that further activate the Wnt/β-catenin 
signaling pathway despite having mutations that stabilize 
β-catenin [38]. Therefore, the idea that extracellular 
Wnt inhibitors have novel functions based on the 
earlier assumption that mutations in APC or β-catenin 
would render cells completely independent of canonical 
Wnt/β-catenin signaling needs to be re-evaluated. Our 
data show that DKK-1 does not affect β-catenin/TCF 
transcriptional activity in APC/KRAS mutant DLD-1 cells 
(Supplementary Fig. S3A) and we propose that nuclear 
DKK-1 plays an important functional role in these cells, 
as well as in vivo. However, we cannot rule out effects of 
extracellular DKK-1 mediated through LRP5/6 binding at 
the plasma membrane. 
The apparent paradoxical behavior of DKK-1 as a 
tumor suppressor and an inducer of chemoresistance may 
be explained by its distinct roles in the cytoplasm and 
nucleus and the non-synchronous loss of its expression in 
both cell compartments. The decrease in nuclear DKK-
1 found at early stages may facilitate tumor progression 
based on the results of the ChIP analysis: nuclear DKK-1 
regulates genes with antiproliferative action (i.e., NRG1, 
NRG3, MAP2K3, PREX2, FAM5B) and involved in 
apoptosis (i.e., BCL2A1, DAPK1) (GSE31170), which 
may add to the action of extranuclear DKK-1 inhibiting 
β-catenin target genes such as c-MYC or CCND1/cyclin 
D1. At later stages in human tumors, systemic therapy 
can cause the selection of tumor cells with high nuclear 
DKK-1 that by inducing genes such as ALDH1A1 and 
REPS2 may be responsible for chemoresistance. Thus, 
DKK-1 seems to have a dual action in colon cancer, that is 
analogous to that of transforming growth factor (TGF)-β 
[39, 40], a suppressive action at early stages, by inhibiting 
cell proliferation by both Wnt-dependent and -independent 
mechanisms, and a tumor promoting action at later stages 
of progression, by inducing chemoresistance.
The induction by DKK-1 of ALDH1A1 and REPS2 
genes that are involved in cellular detoxification explains 
the co-expression of nuclear DKK-1 and these target 
genes in tumors of patients with poor outcome after 
chemotherapy. Thus, ALDH1A1 and REPS2 (mutated in 
14/700, (2%) of colon tumors, and in 4/700, (0.57%) of 
colon tumors, respectively; Cosmic database) seem to be 
major mediators of nuclear DKK-1 effects. The precise 
mechanism by which DKK-1 induces ALDH1A1 remains 
to be elucidated. In mouse osteosarcoma cells, Dkk-1 
has been recently shown to activate ALDH1 via the non-
canonical Jun-mediated Wnt pathway [41], which however 
is not affected in our human CRC cells. For REPS2, the 
coincidence of transcriptomic and ChIP-Seq analyses 
indicates a direct transcriptional regulation by DKK-1. 
A number of recent studies propose an important 
role of ALDH1A1 in the response to chemotherapy of 
patients with colon cancer or other neoplasias. Thus, 
colon cancer stem cells secrete high levels of ALDH1A1 
that cause extracellular detoxification of maphosphamide 
[23] and ALDH1A1 also confers resistance of COLO 
205 cells to cyclophosphamide [42]. Consistently, 
ALDH1A1 expression in colorectal adenoma is 
associated with a higher risk of metachronous adenoma 
independent of adenoma size or histopathology [43]. 
CRC patients with circulating tumor cells expressing 
ALDH1, survivin and MRP5 have shorter PFS [44], 
and ALDH1A1 rs1342024 polymorphism associates 
with shorter time to tumor recurrence [26]. ALDH1A1 
is also associated with worse PFS and OS in clear cell 
renal cell carcinoma [45] and breast cancer patients 
treated with neo-adjuvant chemotherapy [46]. Moreover, 
ALDH1A1 expression associates with chemoresistance of 
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cultured and xenografted ovarian cancer and pancreatic 
adenocarcinoma cells [47, 48]. Likewise, gastric cancer 
cells with high level of ALDH1A1 expression are more 
resistant to 5-FU and cis-diamminedichloroplatinium than 
those cells with lower level [49].
Our group has previously reported that DKK-1 gene 
expression is downregulated in colon cancer as compared 
to healthy adjacent tissue [50] and that this is partially due 
to promoter methylation of the gene in advanced stages 
of progression (Dukes’ C and D) [8]. Those studies were 
performed assessing the relative amount of DKK-1 RNA 
in healthy vs. tumor tissue. In view of our current work, 
it is not only the amount but also the location of DKK-
1 that matters, so we suggest that future assessments of 
DKK-1 status, at least in CRC, must be performed by 
immunodetection procedures.
We previously established that the half-life of DKK-
1 RNA is 2.0 h in SW480-ADH cells [9] and it has been 
reported to be 2.3 h in HeLa cells [51] and 2.25 or 1 h 
in SW480 cells depending on the culture medium [52]. 
We are not aware of any study of DKK-1 protein stability 
and do not know whether nuclear and extranuclear DKK-1 
protein differ in half-life.
In summary, we provide evidence for unpredicted, 
Wnt-independent gene regulatory activity of DKK-1 
within the nucleus that is associated with chemoresistance 
and decreased survival in CRC patients. Our findings may 
help to clarify the role of DKK-1 as a tumor suppressor 
or metastasis promoter [21]. Discrepancies and conflicting 
data present in the literature may depend not only on 
the type of cancer but, at least in colorectal neoplasias, 
also on the location of DKK-1 protein and the stage of 
tumor progression: the presence of DKK-1 within the 
cell nucleus seems to be specifically responsible for 
drug resistance and so, the analysis of the subcellular 
distribution of DKK-1 is warranted. We propose nuclear 
DKK-1 as a biomarker for predicting benefit to systemic 
therapy in metastatic CRC. 
METHODS
Cell culture
SW480-ADH, DLD-1 and RKO cells were cultured 
in DMEM supplemented with 10% fetal calf serum (FCS) 
(both from Invitrogen). Cell lines were originally obtained 
from the American Type Culture Collection (ATCC) and 
authenticated using the GenePrint® 10 System (Promega), 
which allows co-amplification and three-color detection 
of ten human loci: TH01, TPOX, vWA, Amelogenin, 
CSF1PO, D16S539, D7S820, D13S317, D21S11 and 
D5S818. Short Tandem Repeats profiles were sent for 
comparison against cell line datebases (ATCC, DSMZ). 
Last test was done on February 2014. Immortalized 
mouse neonatal hepatocytes were provided by Dr. A. 
Martínez (Instituto de Investigaciones Biomédicas, 
Madrid). For transfection we used the jetPEI reagent 
(PolyPlus Transfection). Firefly (Luc) and Renilla 
reniformis luciferase (Rluc) activities were measured 
separately using the Dual Luciferase kit (Promega). Luc 
activity was normalized to Rluc activity. All experiments 
were performed at least in triplicate. To study β-catenin 
transcriptional activity we used the TOPFlash and 
FOPFlash plasmids provided by Dr. H. Clevers (Utrecht, 
The Netherlands).
Subcellular fractionation
Whole-cell extracts were obtained in RIPA buffer 
as described elsewhere [53], and cytosolic and nuclear 
fractions were obtained as reported [54]. Protein 
concentration was measured using the Bio-Rad DC protein 
assay kit.
Patients
Formalin-fixed paraffin-embedded 3 µm tissue 
sections from human non-pathological colon (n = 16) and 
small intestine (n = 16), colorectal adenomas (n = 76) 
and primary tumors from metastatic colorectal (mCRC) 
patients (n = 699) were retrieved from Fundación Jiménez 
Díaz Biobank. Tumor specimens were retrospectively 
selected from consecutive mCRC patients (1998-2009), 
which had fulfilled the following criteria: adenocarcinoma, 
metastatic disease, no neoadjuvant therapy, available 
tissue and clinical follow up. Demographic data are shown 
in Supplementary Table S1. Clinical data and follow up 
were collected from medical clinical records by medical 
oncologists. The study was approved by the Ethics 
Committee of the institution (PIC 23/2012). 
Immunofluorescence, immunohistochemical and 
confocal microscopy analyses of human tissues 
and cultured cells
Staining of human tissues was performed as 
described [50] using anti-DKK-1 (Cell Signaling 
Technology, #4687; Santa Cruz Biotechnology, sc-
14949), anti-ALDH1A1 (R&D Systems, MAB5869, clone 
703410), anti-REPS2 (Novus Biologicals, NBP1-80891), 
anti-AKR1C3 (Abcam, ab170530), and anti-chromogranin 
A (Dako, M0869, clone DAK-A3) antibodies. DKK-1 
expression was determined in primary tumors (diagnostic 
samples) before chemotherapy administration. Intensity 
for nuclear and cytoplasmic DKK-1 was scored by 
a computerized measurement using the Nuance FX 
Multispectral Imaging System (CRI Caliper Life Sciences) 
as described [55] by two researchers (FR and SZ). For 
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immunofluorescence analyses, cells were rinsed once in 
PBS, fixed in 3.7% paraformaldehyde for 15 min at RT 
and rinsed once in 0.1 M glycine and twice in PBS. They 
were permeabilized in 0.5% Triton X-100 and then washed 
three times in PBS. The non-specific sites were blocked 
by incubation with PBS containing 1% goat serum for 
30 min at RT. Next, cells were incubated with a rabbit or 
goat polyclonal antibodies against DKK-1 (Cell Signaling 
Technology, #4687; Santa Cruz Biotechnology, sc-14949), 
mouse monoclonal against V5-epitope (Invitrogen, R960-
25) and either goat polyclonal antibodies to lamin B (Santa 
Cruz Biotechnology, sc-6216) or mouse monoclonal 
antibodies to fibrillarin (Abcam, ab4566, clone 38F3) 
or to TMG-cap which recognizes the 5’ cap structure of 
spliceosomal snRNAs (Oncogene Research Products, 
NA02, clone K121) diluted in PBS for 3 h at RT or 
overnight at 4ºC. After four washes in PBS, cells were 
incubated with secondary antibodies for 45 min at RT, 
washed and mounted in VectaShield (Vector Laboratories). 
Confocal microscopy was performed with a LSM510 
laser scanning microscope (Carl Zeiss) equipped with 
argon (488 nm), HeNe (543 nm) and HeNe (633 nm) ion 
lasers. All confocal scans were acquired with the LSM510 
software using a Plan Apochromat 63x NA 1.4 objective 
(Carl Zeiss). For double or triple labeling experiments, 
images of the same confocal plane were sequentially 
recorded and pseudocolor images were generated and 
superimposed. TIFF images were further processed using 
Photoshop (CS3, Adobe Systems) for presentation.
Western blotting
Western blotting analyses were performed 
as described [53]. Antibodies: DKK-1 (Santa Cruz 
Biotechnology, sc-14949; Cell Signaling Technology 
#4687), β-tubulin (Sigma-Aldrich, T4026), c-MYC 
(Santa Cruz Biotechnology, sc-40, clone 9E10), cyclin 
D1 (Santa Cruz Biotechnology sc-718), lamin B (Santa 
Cruz Biotechnology, sc-6216), V5 (Invitrogen, R960-25), 
β-actin (Cell Signaling Technology, #5125, clone 13E5), 
phospho-JNK (Cell Signaling Technology, #9251), JNK 
(Santa Cruz Biotechnology, sc-474), phospho-GS S641 
(Cell Signaling Technology, #3891), GS (Cell Signaling 
Technology, #3886, clone 15B1). Specific DKK-1 
antibody blocking peptide (Santa Cruz Biotechnology, 
Y-17P) was used for control purposes.
In situ transcriptional activity
Active transcription sites were labelled by 
incorporation of 5’-fluorouridine (5’-FU, Sigma) into 
nascent RNA as described [56]. Briefly, cells were grown 
to subconfluence on glass coverslips. 5’-FU was added to 
the culture medium at 2 mM for 20 min. The cells were 
then fixed in 3.7% paraformaldehyde in HPEM buffer 
(HPEM 2x: 60 mM Hepes, 130 mM Pipes, 20 mM EGTA, 
and 4 mM MgCl2.6H2O) containing 0.5% Triton X-100 
for 10 min. The incorporation of 5’-FU into nascent RNA 
was detected by incubation for 1 h at 37ºC with a mouse 
monoclonal antibody against halogenated UTP (anti-BrdU, 
Sigma, clone BU-33), diluted 1:50 in PBS. The samples 
were then washed in 0.01 % Tween 20 in PBS, incubated 
for 45 min with anti-mouse FITC-conjugated secondary 
antibody (Jackson ImmunoResearch), and mounted with 
the anti-fading medium Vectashield (Vector Laboratories).
Immunoelectron microscopy
For double immunogold electron microscopy 
detection of nascent RNA and DKK-1, SW480-ADH 
cells were cultured in the presence of 5’-FU to a final 
concentration of 2 mM for 20 min. Cells were fixed with 
4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M 
cacodilate buffer for 30 min at RT. After fixation, cells 
were scrapped off, transferred to an eppendorf tube, 
and centrifuged for 10 min at 12,000 rpm in a minifuge. 
Cell pellets were washed with 0.1 M cacodylate buffer, 
dehydrated in increasing concentrations of methanol 
at -20ºC, embedded in Lowicryl K4M at -20ºC, and 
polymerized by ultraviolet irradiation. Ultrathin sections of 
60 nm thickness were obtained by using an ultramicrotome 
(Ultracut UCT, Leica, Germany), mounted on nickel 
grids, and sequentially incubated with 0.1 M glycine in 
PBS for 15 min and 5% BSA in PBS for 30 min, and the 
primary antibodies diluted in 50 mM Tris HCl (pH 7.6) 
containing 1% BSA and 0.1 M glycine. The incorporation 
of 5’-FU into nascent RNA was detected with the mouse 
monoclonal anti-BrdU antibody; sections were incubated 
for 2 h at 37ºC. After labeling for 5’-FU incorporation, 
ultrathin sections were incubated with a rabbit polyclonal 
anti-DKK1 antibody (Cell Signaling Technology, #4687) 
overnight at RT. Subsequently, ultrathin sections were then 
incubated with secondary antibodies, goat anti-rabbit or 
anti-mouse IgG, coupled to 10 nm or 15 nm gold particles, 
respectively (BioCell; diluted 1:50 in PBS containing 
1% BSA). Following immunogold labeling, the grids 
were stained with uranyl acetate and examined under a 
Phillips EM208 electron microscope operated at 60 kV. As 
controls, ultrathin sections were treated as described above 
but omitting primary antibodies. 
ChIP-sequencing assay
Chromatin immunoprecipitation (ChIP) experiments 
were performed basically as described [57] using a DKK-1 
antibody from Cell Signaling Technology (#4687). ChIP 
samples were processed into sequencing libraries with a 
ChIP-Seq sample preparation kit (Illumina) in accordance 
with the manufacturer’s instructions. Briefly, each sample 
was electrophoresed on agarose gel and a fraction of 100-
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200 bp was taken. Extracted DNA was processed through 
subsequent enzymatic treatments of end-repair, dA-tailing, 
and ligation to adapters as in Illumina’s “ChIP Sequencing 
Sample Prep Guide” (part # 11257047 Rev. A), with the 
exception that gel extraction was replaced with Agencourt 
AMPure XP (Beckman Coulter) bead purification. Each 
adapter-ligated library was PCR amplified with Illumina 
PE primers for 15 cycles. Independent aliquots were 
done with Phusion High-Fidelity DNA pol (Finnzymes 
Reagents) and Accuprime GC Rich pol (Invitrogen), and 
pooled after amplification. The resulting purified DNA 
libraries were applied to an Illumina flow cell for cluster 
generation and sequenced on the Genome Analyzer IIx 
(GAIIx; Illumina) following manufacturer’s protocols.
Unfiltered 40 bp sequence reads were aligned 
against the human reference genome hg18 (NCBI build 
36.1, March 2006) using Illumina’s ELANDv2 algorithm 
on its “eland_extended” mode from within CASAVA-1.7 
package. Raw sequences were defined as reads passing 
purity filter before genome alignment. Only the reads with 
a unique alignment in the reference genome (“s_N_sorted.
txt” files) were used for the peak detection, which was 
performed with MACS (Model-based Analysis of ChIP-
Seq). Peaks were called selecting default parameters for 
P value cut-off (default 1e-5) and modelfold (10, 30) for 
high-confidence fold-enrichment, where genomic DNA of 
mock and input samples were used as negative controls. 
The experimental settings, sequences and analysis 
protocols of the ChIP-seq experiment are deposited in 
GEO accession no. GSE31170.
Gene expression analysis
Microarray analyses were performed using RNAs 
obtained from three independent dishes of DLD-1/Mock 
and DLD-1/DKK-1 cells that were treated with doxycyclin 
(10 µg/ml) for 24 h. Total cellular RNA was isolated 
using the RNeasy kit (Qiagen) according to supplier’s 
specifications. The quantity and quality of the total RNAs 
obtained were determined using 6000 Nano Chips (Agilent 
Technologies). Total RNA samples were then processed 
for hybridization on Gene Chip Human Gene 1.0 ST 
Array (Affymetrix) using standard Affymetrix protocols 
at the Genomics and Proteomics Facility of Centro de 
Investigación del Cáncer (Salamanca, Spain).
Analysis for differential expression was performed 
using the R platform for statistical analysis (R Foundation 
for Statistical Computing, Vienna) and several packages 
from the Bioconductor project (http://www.bioconductor.
org/). The raw data were imported into R and preprocessed 
using the affy package and the robust multichip average 
method. To identify differentially expressed genes, 
we used the limma package. Correction for multiple 
testing was accomplished by controlling the FDR using 
published methods [58]. The experimental settings and 
raw data obtained in this experiment are deposited in GEO 
accession no. GSE35272.
Statistical analysis
Statistical analyses were conducted using SPSS 
v13.0 (SPSS Inc, Chicago, IL). All reported P values 
are two-sided. Prognostic and predictive effects were 
assessed using as clinical endpoints progression-free 
survival (PFS) and overall survival (OS) from metastatic 
event. PFS was calculated from the date of diagnosis 
of metastatic disease to the date when progression was 
confirmed. OS from metastatic event was determined as 
the time elapsed from the date of metastasis diagnosis to 
the date of death from any cause or the date of last follow-
up. The prognostic analysis considered the influence 
of factors in all patients using simple Cox proportional 
hazards modeling on PFS and OS, and in multivariable 
models adjusting for other prognostic factors in this 
population. Kaplan-Meier curves were also plotted. For 
the predictive analysis, Cox proportional hazards models 
were used to estimate hazard ratios (HRs) with 95% CIs 
for metastatic treatment received stratified by factor status. 
This work was performed in accordance with Reporting 
Recommendations for Tumor Marker Prognostic Studies 
(REMARK) guidelines [59]. In vitro results were 
expressed as mean ± SD unless otherwise specified. 
ANOVA test was used for analysis of DKK-1 and target 
genes in human samples.
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